ストックスクリーナーアプリを入手
25.15
2.00%
-0.55
前日終値:
$25.70
開ける：
$26.06
24時間の取引高:
89,095
Relative Volume:
0.11
時価総額：
$2.22B
収益：
$23.38M
当期純損益:
$-155.22M
株価収益率:
-17.34
EPS:
-1.45
ネットキャッシュフロー:
$-134.36M
1週間 パフォーマンス:
-2.61%
1か月 パフォーマンス:
-8.25%
6か月 パフォーマンス:
-25.31%
1年 パフォーマンス:
-28.49%
1日の値動き範囲:
$25.08
$26.23
1週間の範囲:
$24.20
$26.23
52週間の値動き範囲:
$24.20
$47.73
Ideaya Biosciences Inc Stock (IDYA) Company Profile
名前
Ideaya Biosciences Inc
セクター
電話
650-443-6209
住所
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
IDYA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
25.18 | 2.22B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.18 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.50 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
627.20 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.97 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.57 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-11-05 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 開始されました | Mizuho | Outperform |
| 2024-03-08 | 開始されました | BTIG Research | Buy |
| 2023-08-08 | 開始されました | SVB Securities | Outperform |
| 2023-05-24 | 開始されました | Goldman | Buy |
| 2023-04-24 | アップグレード | Stifel | Hold → Buy |
| 2023-03-23 | 開始されました | Berenberg | Buy |
| 2023-02-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-12-28 | 開始されました | CapitalOne | Overweight |
| 2022-10-27 | 開始されました | Citigroup | Buy |
| 2022-08-15 | ダウングレード | Stifel | Buy → Hold |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2022-03-10 | アップグレード | Stifel | Hold → Buy |
| 2021-09-23 | 開始されました | Stifel | Hold |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-03-11 | 開始されました | Guggenheim | Buy |
| 2020-10-07 | 開始されました | Wedbush | Outperform |
| 2020-09-01 | 開始されました | Northland Capital | Outperform |
| 2020-07-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-06 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-13 | 開始されました | ROTH Capital | Buy |
| 2019-10-17 | 開始されました | Oppenheimer | Outperform |
| 2019-09-10 | 開始されました | Robert W. Baird | Outperform |
| 2019-06-17 | 開始されました | Citigroup | Buy |
| 2019-06-17 | 開始されました | JP Morgan | Neutral |
| 2019-06-17 | 開始されました | Jefferies | Buy |
すべてを表示
Ideaya Biosciences Inc (IDYA) 最新ニュース
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - Kilgore News Herald
Ideaya, Hengrui join hands in $1B deal for phase I ADC targeting DLL3 - BioWorld Online
IDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month LowHere's Why - MarketBeat
Ideaya Biosciences stock hits 52-week low at $24.38 - Investing.com
BTIG maintains buy on Ideaya stock, target at $62 By Investing.com - Investing.com Canada
IDEAYA Biosciences (IDYA): A Down Year Presents a Window of Opportunity for Investors - MSN
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald
IDEAYA Biosciences Awards Stock Options to New Employee Under 2023 Inducement Plan (NASDAQ: IDYA) - StockTitan
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - cnhinews.com
Jane Street Group LLC Trims Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Increased by Geode Capital Management LLC - MarketBeat
Barclays PLC Purchases 118,438 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Wellington Management Group LLP Trims Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Sets New 52-Week LowHere's Why - MarketBeat
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium - The Eastern Progress Online
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - The Eastern Progress Online
Ideaya Biosciences keeps stock target, Outperform on robust medicine pipeline - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Ideaya nominates KAT6/7 inhibitor as development candidate - BioWorld Online
Short Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Declines By 11.2% - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Receives "Outperform" Rating from Wedbush - MarketBeat
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Par - GuruFocus.com
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - Quantisnow
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - The Malaysian Reserve
IDEAYA nominates IDE251 for cancer treatment development By Investing.com - Investing.com South Africa
IDEAYA Announces Development Candidate Nomination of IDE251, a P - GuruFocus.com
IDEAYA nominates IDE251 for cancer treatment development - Investing.com
IDEAYA's Novel Cancer Drug Shows Promise for Breast & Lung Cancer Treatment - StockTitan
IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years - Yahoo Finance
Indo-Asian News Service - IANS India Pvt Ltd
State Street Corp Boosts Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.67 Consensus Price Target from Analysts - MarketBeat
(IDYA) Proactive Strategies - Stock Traders Daily
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week LowShould You Sell? - MarketBeat
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 - Kilgore News Herald
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - The Eastern Progress Online
Ideaya Biosciences stock hits 52-week low at $25.16 - Investing.com India
Ideaya Biosciences stock hits 52-week low at $25.16 By Investing.com - Investing.com UK
IDEAYA Biosciences' SWOT analysis: precision oncology stock poised for growth - Investing.com
BNP Paribas Financial Markets Decreases Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events - Victoria Advocate
Ideaya Biosciences Inc (IDYA) 財務データ
収益
当期純利益
現金流量
EPS
Ideaya Biosciences Inc (IDYA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Throne Jason | Chief Legal Officer |
Jun 27 '24 |
Option Exercise |
7.77 |
53,484 |
415,587 |
63,484 |
| WHITE MICHAEL ANTHONY | Chief Scientific Officer |
May 29 '24 |
Option Exercise |
12.86 |
28,500 |
366,510 |
28,500 |
| WHITE MICHAEL ANTHONY | Chief Scientific Officer |
May 29 '24 |
Sale |
36.24 |
28,500 |
1,032,884 |
0 |
| Hata Yujiro S | President and CEO |
May 15 '24 |
Option Exercise |
4.31 |
83,856 |
361,419 |
761,743 |
| Hata Yujiro S | President and CEO |
May 14 '24 |
Option Exercise |
4.31 |
56,711 |
244,424 |
734,598 |
| Hata Yujiro S | President and CEO |
May 16 '24 |
Option Exercise |
4.31 |
34,433 |
148,406 |
712,320 |
| Hata Yujiro S | President and CEO |
May 15 '24 |
Sale |
42.90 |
83,856 |
3,597,756 |
677,887 |
| Hata Yujiro S | President and CEO |
May 14 '24 |
Sale |
41.61 |
56,711 |
2,359,780 |
677,887 |
| Hata Yujiro S | President and CEO |
May 16 '24 |
Sale |
41.81 |
34,433 |
1,439,754 |
677,887 |
| Ruiz Briseno Andres | See Remarks |
Feb 09 '24 |
Sale |
46.02 |
2,000 |
92,045 |
24,531 |
1.01%
大文字化:
|
ボリューム (24 時間):